Corbus Pharmaceuticals Holdings
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Corbus Pharmaceuticals Holdings generated cash of -$36,100,473, which is more than the previous year. Cash used in financing activities reached the amount of -$2,820,522 last year. Net change in cash is therefore -$3,279,034.
Cash Flow
| 2014 | -2.36M | -64.44K | 8.38M |
|---|---|---|---|
| 2015 | -4.64M | -114.03K | 10.83M |
| 2016 | -13.57M | -353.03K | 16.74M |
| 2017 | -27.79M | -707.42K | 76.00M |
| 2018 | -30.06M | -2.30M | 11.41M |
| 2019 | -45.72M | -2.74M | 38.46M |
| 2020 | -99.68M | -484.49K | 154.87M |
| 2021 | -48.18M | -73.41M | 60.82M |
| 2022 | -37.54M | 30.07M | -533.61K |
| 2023 | -36.10M | 35.64M | -2.82M |
0SZI.L Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 17.67M | 25.67M | 86.45M | 31.74M | 41.74M | 62.69M | 15.19M | 12.37M | 6.26M | 303.02K |
Operating activities | ||||||||||
Net income | -44.60M | -42.34M | -45.64M | -111.26M | -71.45M | -55.67M | -32.42M | -19.99M | -8.85M | -2.54M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 640.60K | 1.48M | 1.63M | 1.69M | 1.22M | 493.93K | 255.65K | 87.66K | 43.94K | 10.40K |
Stock-based compensation expense | 3.47M | 5.71M | 9.48M | 12.45M | 11.98M | 0 | 5.69M | 3.16M | 1.15M | 193.12K |
| Deferred income tax benefit | 3.47M | 5.71M | 9.48M | 12.45M | 11.98M | 0 | 5.69M | 3.16M | 1.15M | 193.12K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 1.61M | 1.06M | 5M | 12.5M | 1M | -1M | 0 | 0 |
Inventories | 0 | 0 | -1.61M | -1.06M | 9.57M | 5.39M | -404.23K | 2.10M | 0 | 0 |
Accounts payable | 1.02M | -256.83K | -5.95M | -3.46M | 4.36M | 3.90M | -885.79K | 1.89M | 972.19K | 170.23K |
Cash generated by operating activities | -36.10M | -37.54M | -48.18M | -99.68M | -45.72M | -30.06M | -27.79M | -13.57M | -4.64M | -2.36M |
Investing activities | ||||||||||
Purchases Of Investments | -33.88M | -86.34M | -87.26M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -13.44K | -54.17K | -484.49K | -2.74M | -2.30M | -707.42K | -353.03K | -114.03K | -64.44K |
Acquisitions Net | 0 | 8.1K | 23.9K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 35.64M | 30.07M | -73.41M | -484.49K | -2.74M | -2.30M | -707.42K | -353.03K | -114.03K | -64.44K |
Financing activities | ||||||||||
Common Stock Issued | 244.30K | 0 | 60.76M | 142.20M | 40.67M | 12.05M | 78.89M | 16.69M | 11.32M | 10.30M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -2.87M | -533.61K | -57.78K | -951.87K | 357.97K | -434.44K | 57.27K | -242.18K | 17.63K | -247.00K |
Cash used in financing activities | -2.82M | -533.61K | 60.82M | 154.87M | 38.46M | 11.41M | 76.00M | 16.74M | 10.83M | 8.38M |
Net Change In Cash | -3.27M | -8.00M | -60.77M | 54.70M | -9.99M | -20.94M | 47.50M | 2.81M | 6.07M | 5.95M |
Cash at end of period | 14.39M | 17.67M | 25.67M | 86.45M | 31.74M | 41.74M | 62.69M | 15.19M | 12.33M | 6.26M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |